|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2010-3-29
|
|
pubmed:abstractText |
Thai adult males (N = 85) with acute Plasmodium vivax malaria and normal glucose-6-phosphate dehydrogenase screening were randomized to receive 30 mg or 60 mg primaquine daily for 7 days (N = 43 and 42, respectively). The regimens were well tolerated and all patients recovered fully. Median fever clearance (47 hours; range 4 to 130 hours), mean + or - SD parasite clearance times (87.7 + or - 25.3 hours), gametocyte clearance, and adverse effects were similar in the 2 groups. Two patients, 1 from each group, had a 30% reduction in hematocrit. The cumulative 28 day relapse rate (95% confidence interval) by Kaplan Meier survival analysis was 29% (16-49%) in the 30 mg group compared with 7% (2-24%) in the 60 mg group; P = 0.027. Comparison with previous data obtained at this same site suggests that the recurrences comprised approximately 17% recrudescences and 12% relapses in the 30 mg/day group compared with 3% recrudescences and 4% relapses in the 60 mg/day group. These data suggest that the dose-response relationships for primaquine's asexual stage and hypnozoitocidal activities in-vivo are different. A 1 week course of primaquine 60 mg daily is an effective treatment of vivax malaria in this region.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/20348496-10674098,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20348496-10674681,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20348496-10817728,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20348496-11712091,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20348496-12932090,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20348496-13242948,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20348496-17330781,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20348496-18458306,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20348496-19597012,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20348496-8036680,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20348496-8133114,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20348496-9696733
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1476-1645
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
82
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
542-7
|
|
pubmed:dateRevised |
2010-9-28
|
|
pubmed:meshHeading |
pubmed-meshheading:20348496-Adolescent,
pubmed-meshheading:20348496-Adult,
pubmed-meshheading:20348496-Animals,
pubmed-meshheading:20348496-Antimalarials,
pubmed-meshheading:20348496-Dose-Response Relationship, Drug,
pubmed-meshheading:20348496-Drug Administration Schedule,
pubmed-meshheading:20348496-Humans,
pubmed-meshheading:20348496-Malaria, Vivax,
pubmed-meshheading:20348496-Male,
pubmed-meshheading:20348496-Middle Aged,
pubmed-meshheading:20348496-Plasmodium vivax,
pubmed-meshheading:20348496-Primaquine,
pubmed-meshheading:20348496-Thailand,
pubmed-meshheading:20348496-Young Adult
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
A comparison of two short-course primaquine regimens for the treatment and radical cure of Plasmodium vivax malaria in Thailand.
|
|
pubmed:affiliation |
Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand. sasithon@tropmedres.ac
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
